Trading Report: Today, Syros Pharmaceuticals Inc. (SYRS) Upgrade by The Zacks Investment Research to Hold

Today, Syros Pharmaceuticals Inc. (SYRS) Upgrade by The Zacks Investment Research to Hold

Zacks Investment Research upgraded shares of Syros Pharmaceuticals Inc. (NASDAQ:SYRS) from a sell rating to a hold rating in a report issued on Wednesday morning.

According to Zacks, “Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company’s product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “

A number of other research analysts have also recently issued reports on the stock. Piper Jaffray Cos. reaffirmed a buy rating and issued a $20.00 target price on shares of Syros Pharmaceuticals in a report on Thursday, September 22nd. HC Wainwright reaffirmed a hold rating and issued a $10.00 target price on shares of Syros Pharmaceuticals in a report on Friday, September 9th. Finally, Wedbush reaffirmed an outperform rating and issued a $18.00 target price on shares of Syros Pharmaceuticals in a report on Monday, November 14th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company has an average rating of Buy and a consensus target price of $19.60.

Shares of Syros Pharmaceuticals (NASDAQ:SYRS) opened at 13.33 on Wednesday. The stock’s market cap is $311.66 million. Syros Pharmaceuticals has a 52-week low of $8.16 and a 52-week high of $21.50. The stock’s 50 day moving average is $13.48 and its 200 day moving average is $13.08.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its earnings results on Monday, November 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.54) by $0.11. On average, equities analysts expect that Syros Pharmaceuticals will post ($4.03) earnings per share for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System acquired a new stake in Syros Pharmaceuticals during the third quarter valued at approximately $137,000. Spark Investment Management LLC purchased a new stake in shares of Syros Pharmaceuticals during the third quarter worth about $160,000. Hamilton Lane Advisors LLC purchased a new stake in shares of Syros Pharmaceuticals during the third quarter worth about $193,000. Morgan Stanley purchased a new stake in shares of Syros Pharmaceuticals during the third quarter worth about $469,000. Finally, AWM Investment Company Inc. purchased a new stake in shares of Syros Pharmaceuticals during the third quarter worth about $660,000. Institutional investors and hedge funds own 54.56% of the company’s stock.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing treatments for cancer and immune-mediated diseases. The Company’s gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets.

Related posts

Leave a Comment